Arginine + glutamine + HMB is estimated at 35.5% of formulation revenue in 2026 because clinicians recognize its wound-focused nutrient profile. Diabetic foot ulcers hold 39.8% and powder sachets account for 44.5%, with continued use governed by nutrition screening and payment routes after specialist care.